IRLAB Therapeutics AB Class A's total assets for Q2 2025 were kr116.50M, a decrease of -27.06% from the previous quarter. DE:6IRA total liabilities were kr144.18M for the fiscal quarter, a -7.03% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.